Login to Your Account

Stem cell firm Reneuron advances with studies in stroke, ischemia

By Nuala Moran
Staff Writer

Friday, March 28, 2014
LONDON – Reneuron plc has the go-head to start two new trials of its autologous stem cell therapy, receiving approval to use a new cryopreserved formulation that would allow the product to be available off the shelf, surmounting one of the major hurdles to commercialization.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription